SG10201810357WA - Ly75 as cancer therapeutic and diagnostic target - Google Patents

Ly75 as cancer therapeutic and diagnostic target

Info

Publication number
SG10201810357WA
SG10201810357WA SG10201810357WA SG10201810357WA SG10201810357WA SG 10201810357W A SG10201810357W A SG 10201810357WA SG 10201810357W A SG10201810357W A SG 10201810357WA SG 10201810357W A SG10201810357W A SG 10201810357WA SG 10201810357W A SG10201810357W A SG 10201810357WA
Authority
SG
Singapore
Prior art keywords
cancer
diagnostic target
cancer therapeutic
therapeutic
leukaemia
Prior art date
Application number
SG10201810357WA
Other languages
English (en)
Inventor
James Edward Ackroyd
Original Assignee
Oxford Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47429281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201810357W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford Biotherapeutics Ltd filed Critical Oxford Biotherapeutics Ltd
Publication of SG10201810357WA publication Critical patent/SG10201810357WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201810357WA 2012-11-07 2013-11-06 Ly75 as cancer therapeutic and diagnostic target SG10201810357WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1220010.1A GB201220010D0 (en) 2012-11-07 2012-11-07 Therapeutic amd diagnostic target

Publications (1)

Publication Number Publication Date
SG10201810357WA true SG10201810357WA (en) 2018-12-28

Family

ID=47429281

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201810357WA SG10201810357WA (en) 2012-11-07 2013-11-06 Ly75 as cancer therapeutic and diagnostic target
SG11201503363WA SG11201503363WA (en) 2012-11-07 2013-11-06 Ly75 as cancer therapeutic and diagnostic target

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201503363WA SG11201503363WA (en) 2012-11-07 2013-11-06 Ly75 as cancer therapeutic and diagnostic target

Country Status (15)

Country Link
US (3) US20150297743A1 (https=)
EP (1) EP2917239A1 (https=)
JP (4) JP2016501843A (https=)
KR (1) KR102256552B1 (https=)
CN (2) CN113181372A (https=)
AU (2) AU2013343277B2 (https=)
BR (1) BR112015009438B1 (https=)
CL (1) CL2015001098A1 (https=)
EA (1) EA033649B1 (https=)
GB (1) GB201220010D0 (https=)
HK (1) HK1214611A1 (https=)
NZ (1) NZ707116A (https=)
SG (2) SG10201810357WA (https=)
UA (1) UA117569C2 (https=)
WO (1) WO2014072700A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220010D0 (en) * 2012-11-07 2012-12-19 Oxford Biotherapeutics Ltd Therapeutic amd diagnostic target
CN105745224B (zh) 2013-10-11 2019-11-05 牛津生物疗法有限公司 用于治疗癌症的针对ly75的偶联抗体
AU2016269632B2 (en) 2015-05-29 2021-09-09 Mla Diagnostics B.V. Method for identifying subjects with aggressive melanoma skin cancer at diagnosis
KR101796091B1 (ko) 2016-05-02 2017-11-10 충남대학교 산학협력단 카복실 말단 조절 단백질을 포함하는 두경부암 진단용 바이오 마커 조성물
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CN109685135B (zh) * 2018-12-21 2022-03-25 电子科技大学 一种基于改进型度量学习的少样本图像分类方法
JP7797384B2 (ja) * 2019-11-26 2026-01-13 シーダーズ－サイナイ メディカル センター 循環からミトコンドリアｄｎａ又はゲノムｄｎａを枯渇させることにより疾患及び症状を治療する組成物及び方法
WO2023032994A1 (ja) 2021-08-31 2023-03-09 富士フイルム株式会社 化合物及びこれを用いた標識生体物質
WO2023032996A1 (ja) 2021-08-31 2023-03-09 富士フイルム株式会社 化合物及びこれを用いた標識生体物質
JPWO2023032995A1 (https=) 2021-08-31 2023-03-09
JP2024533459A (ja) * 2021-09-13 2024-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド リンパ球抗原７５（ｌｙ７５）、表面抗原分類１６４（ｃｄ１６４）、またはポリ（ａｄｐ－リボース）ポリメラーゼ１（ｐａｒｐ１）阻害剤を用いた未確定の潜在能をもつクローン性造血（ｃｈｉｐ）の治療方法
JPWO2024143263A1 (https=) 2022-12-26 2024-07-04
CN120752249A (zh) 2023-02-27 2025-10-03 富士胶片株式会社 化合物及使用了该化合物的标记生物物质
WO2024181454A1 (ja) 2023-02-27 2024-09-06 富士フイルム株式会社 化合物及びこれを用いた標識生体物質
KR20260023583A (ko) 2023-08-31 2026-02-20 후지필름 가부시키가이샤 표적화 약물 복합체 및 이것을 포함하는 의약, 및, 화합물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
JP2000512490A (ja) * 1996-05-29 2000-09-26 デレク ナイジェル ジョン ハート 樹状細胞のレセプター
KR20080087184A (ko) * 2001-01-31 2008-09-30 바이오겐 아이덱 인크. 종양질환 치료를 위한 ｃｄ23 길항제의 용도
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
AU2008261951A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
CN101888856B (zh) * 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
EP2159291A1 (en) * 2008-09-01 2010-03-03 Agendia B.V. Means and method for determining tumor cell percentage in a sample
AU2010303304A1 (en) * 2009-10-08 2012-05-17 President And Fellows Of Harvard College Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
TW201247706A (en) * 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
GB201220010D0 (en) * 2012-11-07 2012-12-19 Oxford Biotherapeutics Ltd Therapeutic amd diagnostic target
JP6431104B2 (ja) * 2017-02-27 2018-11-28 オリコン株式会社 マイクロ波を利用した金属蒸気の発生方法

Also Published As

Publication number Publication date
US20190317100A1 (en) 2019-10-17
CN113181372A (zh) 2021-07-30
KR20150082278A (ko) 2015-07-15
BR112015009438A2 (pt) 2017-11-14
JP7079685B2 (ja) 2022-06-02
BR112015009438B1 (pt) 2023-03-14
AU2018203478A1 (en) 2018-06-07
KR102256552B1 (ko) 2021-05-25
WO2014072700A1 (en) 2014-05-15
GB201220010D0 (en) 2012-12-19
CL2015001098A1 (es) 2015-09-25
UA117569C2 (uk) 2018-08-27
EP2917239A1 (en) 2015-09-16
NZ707116A (en) 2019-07-26
HK1214611A1 (zh) 2016-07-29
SG11201503363WA (en) 2015-06-29
US20150297743A1 (en) 2015-10-22
JP2023011880A (ja) 2023-01-24
EA201590694A1 (ru) 2015-09-30
US20210346512A1 (en) 2021-11-11
JP2021011483A (ja) 2021-02-04
AU2018203478B2 (en) 2020-02-06
CN104755496A (zh) 2015-07-01
JP7479435B2 (ja) 2024-05-08
JP2016501843A (ja) 2016-01-21
EA033649B1 (ru) 2019-11-13
AU2013343277A1 (en) 2015-05-07
JP2018188463A (ja) 2018-11-29
AU2013343277B2 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
SG10201810357WA (en) Ly75 as cancer therapeutic and diagnostic target
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
MX369740B (es) Anticuerpos contra claudina 18.2 útiles en el diagnóstico de cáncer.
MX355543B (es) Macrociclos peptidomiméticos.
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
WO2010017515A3 (en) Breast cancer specific markers and methods of use
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MX2020012426A (es) Anticuerpos anti-cd38.
MX383886B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
PH12012502231A1 (en) Anti-human trop-2 antibody having antitumor activity in vivo
PH12014501844B1 (en) Peptidomimetic macrocycles
GB201009222D0 (en) Improved cancer therapy based on tumour associated antigens derived from cyclin D1
TW201611831A (en) Novel antitumoral use of CABAZITAXEL
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
MY174883A (en) Treatment of brain cancer
MX336761B (es) Compuestos para el tratamiento de cancer.
EP3736022A3 (en) Treatment and diagnosis of colon cancer
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2013087929A3 (de) Verfahren zur identifizierung von markersequenzen für gynäkologisches malignom
SG194235A1 (en) Methods of predicting the development of complement-mediated disease
WO2013081645A3 (en) Erbb3 mutations in cancer
WO2013001369A3 (en) Therapeutic and diagnostic target
AP2012006181A0 (en) Targeting PAX2 for the treatment of breast cancer.
PL3857230T3 (pl) Sposoby diagnostyczne dla potrójnie ujemnego raka piersi